Nonagen Bioscience Turns to Peregrine Market Access to Lead Commercialization of Innovative Bladder Cancer Diagnostic Test – PharmaLive


Peregrine Market Access is a full-service marketing partner for the life sciences industry with capabilities in the consulting, communications and execution phases of market access and brand campaigns. Peregrine’s business units include Strategy and Consulting, Market Access Communications, Research and Analytics, Value Modeling, Reimbursement Solutions, Value Stream Public Relations, media and contract account and sales team services. Through its work, Peregrine helps people living with chronic and/or life-threatening illnesses access FDA-approved diagnostics and treatments. Peregrine, with a mission to change the way healthcare is valued in the United States, has been recognized nationally as one of America’s fastest-growing private companies in 2021 by Inc. 5000 The company is headquartered in Saratoga Springs, New York, and also has an office in Santa Monica, California. Learn more at


Nonagen Bioscience is an early-stage biotechnology company focused on reducing the global burden of cancer through innovative diagnostics. The Los Angeles-based company is committed to bringing to market the best non-invasive diagnostics for cancer detection, therapy selection and disease monitoring. Learn more at

The references: 1. National Cancer Institute. Statistical Cancer Facts: Bladder Cancer. Accessed January 11, 2022. 2. American Cancer Society. Cancer facts and figures 2021. Atlanta, Georgia: American Cancer Society; 2021. 3. Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA/SUO risk group for non-muscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203(3):505-511. doi:10.1097/JU.0000000000000593 4. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790-797. doi:10.1016/j.eururo.2006.01.017 5. Matulay JT, Li R, Hensley PJ, et al. Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacille Calmette-Guérin: implications for clinical trial design. J Urol. 2021;205(6):1612-1621. doi:10.1097/JU.0000000000001633


jenny sparano


[email protected]


About Author

Comments are closed.